http://www.inhibitortargets.com/index.php/2017/11/30/processes-co-operate-promote-tumor-cell-invasion/ 2022-01-14T05:07:14+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/28/cells-migrate-3-dimensional-extracellular-matrix-rounded-morphology/ 2022-01-14T05:07:14+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/28/inhibitors-cells-sensitive-current-chemotherapeutic-drugs/ 2022-01-14T05:07:15+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/27/kinase-activation-implies-conformational-change-involving-activation-loop/ 2022-01-14T05:07:15+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/24/respond-current-inhibitors-b-raf-atm-dna-pk-mek1-aurora-kinases/ 2022-01-14T05:07:15+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/23/case-knockdown-affects-signalling-mapk-modulates-signal-transmission/ 2022-01-14T05:07:15+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/22/result-overlap-identical-vrk1-vrk2-inhibition-patterns/ 2022-01-14T05:07:15+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/20/inhibitors-non-competitive-competitive-included-detected-bind/ 2022-01-14T05:07:15+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/19/kinases-discriminated-small-panel-thirty-eight-inhibitors/ 2022-01-14T05:07:15+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/16/kinases-alternative-conformations-allosterically-regulated/ 2022-01-14T05:07:23+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/16/kinase-inactive-state-structurally-diverse-activated-form/ 2022-01-14T05:07:23+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/14/case-option-porin-mutation-bacteria/ 2022-01-14T05:07:23+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/13/molecular-rationale-observed-behaviour-polar-molecules-tend-decrease/ 2022-01-14T05:07:23+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/13/drug-contact-solvent-possibly-formation-h-bonds/ 2022-01-14T05:07:23+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/09/membranes-resistance-absence-membraneactive-substances/ 2022-01-14T05:07:24+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/08/suggesting-regulate-histone-code-linking-histone-methylation-acetylation/ 2022-01-14T05:07:24+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/08/increases-ing-histone-affinity-directs-acetylation-histone-h3-residue/ 2022-01-14T05:07:24+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/07/arrest-circumvented-mutations-hog1-gene-cells-pre-incubated/ 2022-01-14T05:07:24+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/05/wild-type-kinase-non-mutated-gatekeeper-residue-block-access-lipophilic-pocket/ 2022-01-14T05:07:24+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/03/regulation-gene-expression-mediated-hog1-response-stress/ 2022-01-14T05:07:24+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/11/02/sensitivity-fgfr1-inhibition-additional-work-needed-fully-characterize/ 2022-01-14T05:07:24+00:00 daily 0.9 http://www.inhibitortargets.com/index.php/2017/10/31/fgfr-kinase-inhibitors-clinical-trials-including-brivanib-dovitinib/ 2022-01-14T05:07:24+00:00 daily 0.9